The main aim of this study is to check how effective the treatment with Maribavir has been to remove the CMV viruses from the blood of an adult person with CMV infection after a transplant. Other aims are to learn more about how maribavir is used in normal clinical routine, study the profiles of adults treated with maribavir, and what other treatments have been given, and describe healthcare resources used for CMV management. Only data already available in the medical records of the participants will be reviewed and collected during this study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Viremia Clearance Before the End of Maribavir Treatment
Timeframe: From transplantation date until start of chart abstraction or date of death from any cause, whichever comes first, up to approximately 32 months